Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid <i>in vitro</i> and <i>in vivo</i>

Li, Weijie; Yan, Ruicong; Liu, Yong; He, Chuanchuan; Zhang, Xiaojuan; Lu, Yao; Khan, Muhammad Waseem; Xu, Cenke; Tan, Yang; Xiang, Guangya

doi:10.1080/10717544.2019.1645244

Cited by 24 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This property of Chol liposomes, in the absence of other helper lipids, becomes more pronounced and prevents adverse liposome-protein interactions, aggregation, improves mechanical strength and stability 24 , 45 , 46 , and extending circulation time in vivo 47 . It was reported recently that folate receptor-targeted cholesterol-rich liposomes readily form lipoplexes with Bmi1 siRNA that inhibit tumor growth both in vitro and in vivo 48 . Furthermore, DNA in cholesterol-rich plasmid DNA lipoplexes was afforded full protection from enzymatic degradation and showed good efficacy in a CRISPR-Cas9 application in HEK293 cells 49 .…”

Section: Discussionmentioning

confidence: 99%

Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro

et al. 2020

View full text Add to dashboard Cite

Background: Strategies aimed at inhibiting the expression of the c-myc oncogene could provide the basis for alternative cancer treatment. In this regard, silencing c-myc expression using small interfering RNA (siRNA) is an attractive option. However, the development of a clinically viable, siRNA-based, c-myc silencing system is largely dependent upon the design of an appropriate siRNA carrier that can be easily prepared. Nanostructures formed by the electrostatic association of siRNA and cationic lipid vesicles represent uncomplicated siRNA delivery systems. Methods: This study has focused on cationic liposomes prepared with equimolar quantities of the cytofectin, N,N-dimethylaminopropylamido-succinylcholesteryl-formylhydrazide (MS09), and cholesterol (Chol) for the development of a simple, but effective anti-c-myc onco-nanotherapeutic agent. Liposomes formulated with dioleoylphosphatidylethanolamine (DOPE) in place of Chol as the co-lipid were included for comparative purposes. Results: Liposomes successfully bound siRNA forming lipoplexes of less than 200 nm in size, which assumed globular, bilamellar structures. The liposome formulations were well tolerated in the human breast adenocarcinoma (MCF-7) and colon carcinoma (HT-29) cells, which overexpress c-myc. Lipoplexes directed against the c-myc transcript mediated a dramatic reduction in c-myc mRNA and protein levels. Moreover, oncogene knockdown and anti-cancer effects were superior to that of Lipofectamine™ 3000. Conclusion: This anti-c-myc MS09:Chol lipoplex exemplifies a simple anticancer agent with enhanced c-myc gene silencing potential in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, several suitable delivery carriers and systems have been developed. Table 4 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 summarizes recent DDSs for targeting CSC genes and epigenetics.…”

Section: Ddss For Targeting Csc Genes and Epigeneticsmentioning

confidence: 99%

“…Therefore, it is wise to combine conventional anticancer agents and anti-CSC agents for improved therapeutic response 144 , 145 . Recently, many researchers have reported successful development of co-delivery systems for combination therapy ( Table 5 30 , 31 , 73 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 ; Fig. 7 30 , 31 ).…”

Section: Ddss For Combination Therapymentioning

confidence: 99%

Recent advances in drug delivery systems for targeting cancer stem cells

Duan

Liu

Gao

et al. 2021

Acta Pharmaceutica Sinica B

167

107

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a subpopulation of cancer cells with functions similar to those of normal stem cells. Although few in number, they are capable of self-renewal, unlimited proliferation, and multi-directional differentiation potential. In addition, CSCs have the ability to escape immune surveillance. Thus, they play an important role in the occurrence and development of tumors, and they are closely related to tumor invasion, metastasis, drug resistance, and recurrence after treatment. Therefore, specific targeting of CSCs may improve the efficiency of cancer therapy. A series of corresponding promising therapeutic strategies based on CSC targeting, such as the targeting of CSC niche, CSC signaling pathways, and CSC mitochondria, are currently under development. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for CSC targeting are increasingly being developed. In this review, we summarize the advances in CSC-targeted DDSs. Furthermore, we highlight the latest developmental trends through the main line of CSC occurrence and development process; some considerations about the rationale, advantages, and limitations of different DDSs for CSC-targeted therapies were discussed.

show abstract

“…FA-targeted liposomes may be also used as carriers of genes, which are susceptible for degradation by several nucleases in the serum, so need protection and delivery systems providing enhanced cell uptake and controlled release. A promising strategy for improved anti-tumour effect was achieved by co-delivering of small interfering RNA with cisplatin, doxorubicin and ursolic acid in folate-targeted liposomes [ 94 , 95 , 96 ]. In addition, dendrimers made from cationic polymers can be considered as carriers appropriate for gene delivery, e.g., siRNA [ 97 , 98 ], because they can provide good protective properties against rapid enzyme degradation and effective gene transport to intracellular space.…”

Section: Folic Acid—targeted Nanoparticlesmentioning

confidence: 99%

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid in vitro and in vivo

Abstract: Xiang (2019) Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid invitro and invivo,

Cited by 24 publications

References 47 publications

Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro

Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro

Recent advances in drug delivery systems for targeting cancer stem cells

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Contact Info

Product

Resources

About